A recent genome-wide association study of over 5000 patients from multiple trials reports that enzyme-activity-enhancing genetic variations at the sptlc3 gene locus, which encodes one of the SPT enzyme tetramers, contributed to significantly increased circulating ceramide levels and was associated with CVD and T2DM [222]. The gene discussed is AGXT; the disease is type 2 diabetes mellitus.